Trial reportEuropean heart journal2015
Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes.
Trial report in European heart journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 56 citations in OpenAlex.
- Aging-related immune phenotypes are associated with subclinical coronary atherosclerosis in a middle-aged population: a subcohort of the Swedish CArdioPulmonary bioImage Study.Immunity & ageing : I & A · 2026Article
- Inflammation and Immune Mechanisms in Atherosclerosis.Reviews in cardiovascular medicine · 2026Review
- Treg Immunomodulation Contributes to the Anti-atherosclerotic Effects of Huxin Formula in ApoEChinese journal of integrative medicine · 2024Article
- Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential.Cardiovascular drugs and therapy · 2024Review
- Mini-Review: Immunogenic epitopes in apolipoprotein B-100 for atheroprotective immunization.Frontiers in cardiovascular medicine · 2024Review
- Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets.Frontiers in immunology · 2024Review
- Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease.Biomedicines · 2023Review
- Regulatory T Cells in Atherosclerosis: Is Adoptive Cell Therapy Possible?Life (Basel, Switzerland) · 2023Review
- Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome.Frontiers in immunology · 2023Article
- Circulating Regulatory B-Lymphocytes in Patients with Acute Myocardial Infarction: A Pilot Study.Journal of cardiovascular development and disease · 2022Article
- CD69 expression on regulatory T cells protects from immune damage after myocardial infarction.The Journal of clinical investigation · 2022Article
- The why and how of adaptive immune responses in ischemic cardiovascular disease.Nature cardiovascular research · 2022Article
- The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis.Therapeutic advances in chronic disease · 2022Article
- Restricted T-Cell Repertoire in the Epicardial Adipose Tissue of Non-ST Segment Elevation Myocardial Infarction Patients.Frontiers in immunology · 2022Article
- Recent Advances on the Role and Therapeutic Potential of Regulatory T Cells in Atherosclerosis.Journal of clinical medicine · 2021Review
- Regulatory T Cells: A New Target of Chinese Medicine in Treatment of Atherosclerosis.Chinese journal of integrative medicine · 2021Review
- Article
- Does multivessel revascularization fit all patients with STEMI and multivessel coronary artery disease? A systematic review and meta-analysis.International journal of cardiology. Heart & vasculature · 2021Review
- Review
- ApoB-Specific CD4Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsRegulatory T cells (Treg) exert anti-inflammatory and atheroprotective effects in experimental atherosclerosis. Treg can be induced against specific antigens using immunization strategies associated with clonal restriction. No data exist on Treg in combination with clonal restriction of T cells in patients with acute coronary syndromes (ACS). METHODS AND
resultsAmong T cell subsets characterized by flow cytometry, Treg (CD4(+) CD25(+) CD127(low)) were twice as frequent in coronary thrombi compared with peripheral blood. Treg prevailed among T cell subsets identified in coronary thrombi. To evaluate clonal restriction, genomic DNA was extracted from coronary thrombi and peripheral blood in order to evaluate T cell receptor (TCR) β chain diversity by means of Multi-N-plex PCR using a primer specific for all TCR β V gene segments and another primer specific for TCR β J gene segments. T cell receptor diversity was reduced in thrombi compared with peripheral blood (intra-individual comparisons in 16 patients) with 8 gene rearrangements in the TCR common in at least 6 out of 16 analysed coronary thrombi. Compared with age-matched healthy controls (n = 16), TCR diversity was also reduced in peripheral blood of patients with ACS; these findings were independent of peripheral T cell numbers.
conclusionWe provide novel evidence for a perturbed T cell compartment characterized by clonal restriction in peripheral blood and coronary thrombi from patients with ACS. Our findings warrant further studies on Treg as novel therapeutic targets aimed at enhancing this anti-inflammatory component of adaptive immunity in human atherothrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.